Pneumococcal Disease
Conditions
Keywords
Invasive Pneumococcal Disease (IPD), pneumococcal serotypes
Brief summary
Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program. The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.
Detailed description
open label, one group Purposive sampling of hospitalized children ≤14 years of age with confirmed IPD
Interventions
OTHERno intervention
There is no intervention. This is a non interventional study.
Sponsors
Pfizer
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 14 Years
Healthy volunteers
No
Inclusion criteria
* Children aged 14 years old or less. * Hospitalized in a participating healthcare facility with an IPD. * IPD will be confirmed by isolation of S. pneumoniae from a sterile body site.
Exclusion criteria
* Children \> 14 years of age * Unconfirmed IPD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The serotype distribution of invasive S. pneumoniae isolates of hospitalized children up to 14 years of age after the introduction of the 7-valent conjugate pneumococcal vaccine | yearly |
Secondary
| Measure | Time frame |
|---|---|
| Serotype distribution of resistant S. pneumoniae isolates | yearly |
| Serotype distribution of IPD between immunized and non immunized children ≤14 years of age | yearly |
| Antimicrobial susceptibilities of IPD isolates and rates of resistance to penicillin | yearly |
Countries
Greece
Outcome results
None listed